Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | GFER | P55789 | 1/20 | 0.43 |
| ▸ | HTR6 | P50406 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30312304 | 1.00 | SIGMAR1 (0.48) | SIGMAR1KMT2AKDM4EPOLBTDP1 | |
| SCHEMBL25811446 | 0.82 | HTR6 (0.42) | KMT2AALDH1A1HTR6 | |
| SCHEMBL3712996 | 0.76 | SIGMAR1 (0.73) | SIGMAR1KMT2AKDM4ESMN1; SMN2MAPK1 | |
| SCHEMBL25811425 | 0.75 | PTGDR2 (0.47) | TDP1ALDH1A1HTR6HSD17B10 | |
| SCHEMBL24015624 | 0.74 | HTR6 (0.52) | HTR6 | |
| SCHEMBL4617938 | 0.73 | SIGMAR1 (0.57) | SIGMAR1KMT2AKDM4EPOLBTDP1 | |
| SCHEMBL25811424 | 0.71 | HTR6 (0.50) | HTR6 | |
| SCHEMBL25811430 | 0.71 | PTGDR2 (0.51) | HTR6 | |
| SCHEMBL4618283 | 0.71 | SFRP1 (0.68) | SIGMAR1KMT2ASMN1; SMN2MAPK1ALDH1A1 | |
| SCHEMBL19605706 | 0.70 | HTR6 (0.50) | SMN1; SMN2HTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230218573-A1 | INDOLE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | GALYAN BIO INC (US) | 2023-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230218573-A1 | INDOLE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | HTT, HYPK, PARK7 | SIGMAR1 2141/4885KMT2A 981/4885KDM4E 1465/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.